Siplizumab is under clinical development by ITB-Med and currently in Phase I for Amyotrophic Lateral Sclerosis. According to GlobalData, Phase I drugs for Amyotrophic Lateral Sclerosis have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Siplizumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Siplizumab overview
Siplizumab is under development for the treatment of bone marrow transplant rejection and solid organ transplant rejection such as kidney transplant rejection, hidradenitis suppurativa, type 1 diabetes, amyotrophic lateral sclerosis and liver transplant rejection. It is a humanized version of BTI-322. The therapeutic candidate is an anti-CD2 monoclonal antibody which acts by targeting T cell surface antigen CD2. It is administered through intravenous and subcutaneous route.
It was also under development for the treatment of plaque psoriasis, graft versus host disease (GVHD), T-cell lymphomas like peripheral, natural killer cell lymphomas, cutaneous lymphoma.
ITB-Med overview
ITB-Med (ITBMed) is a biopharmaceutical company that develops specific immunomodulatory biologics for organ and stem cell transplantation and gene therapy. Its lead product candidate, Siplizumab, a recombinant monoclonal antibody, binds to the human CD2 receptor molecule detected on T lymphocytes (T cells), natural killer cells and thymocytes. The activation of T cells leads to transplant rejection in solid organ (kidney) and bone marrow transplantation patients. The unique mechanism of Siplizumab induces alloantigen hyporesponsiveness and has immunomodulatory effect, which down-regulates the rejection response and facilitates the discontinuation of immunosuppression treatment. It conducts research and development programs in scientific collaboration with Columbia University to advance its pipeline. ITBMed is headquartered in Stockholm, Sweden.
For a complete picture of Siplizumab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
